Respiratory Diagnostics
Immunochromatographic and antigen combo tests covering influenza A/B, SARS-CoV-2, RSV, ADV, and Human Metapneumovirus from nasal specimens.
ISO 13485-certified manufacturer supplying rapid diagnostic kits and OEM IVD solutions to distributors and partners across the US, EU, SEA, and China.
Supplier-declared, pending confirmation
Immunochromatographic and antigen combo tests covering influenza A/B, SARS-CoV-2, RSV, ADV, and Human Metapneumovirus from nasal specimens.
Qualitative ICA-based tests detecting carbapenemases, beta-lactamases, and MCR-1 enzyme directly from bacterial colonies, with results in 15 to 30 minutes.
Rapid tests for gastrointestinal pathogens, tuberculosis, and pulmonary biomarkers using ICA and fluorescence immunoassay platforms.
Quantitative FIA kits designed for use on fluorescence readers, providing higher sensitivity for biomarker detection at the point of care.
Flocked and standard swabs with matched viral and universal transport media for reliable specimen collection and preservation.
End-to-end OEM manufacturing from raw material sourcing and assay development through regulatory filing support, white-label packaging, and export documentation.
Entrong Medical holds NMPA Class III Medical Device certification alongside ISO 13485 quality management accreditation, satisfying the documentation requirements of most import regulators in the US, EU, and SEA markets.
The production workshop is designed and operated to US FDA GMP requirements, reducing the compliance burden for distributors entering or already active in the North American market.
Manufacturing spans immunochromatographic (ICA), fluorescence immunoassay (FIA), and molecular diagnostic platforms, allowing distributors to source complementary product lines from a single supplier.
Entrong Medical supports OEM partners from raw material procurement and assay development through white-label packaging and export documentation, covering the entire product lifecycle under one roof.
The EZER AMR range includes CTX-M beta-lactamase groups 1, 2, 8, 9, and 25, OXA-23 carbapenemase, and MCR-1 enzyme detection, addressing a diagnostics segment with growing regulatory and clinical demand globally.